Research about RU58841 /Why it was stopped Research/Science 4/3/2021
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
View this post in the Community →
Similar Community Posts Join
5 / 1000+ resultscommunity ~5 months topical minoxidil + oral finasteride results (swipe images). Slacked with minoxidil this past month, trying to wean off anyways. My last update because I’m hopping off fin and switching to RU in a few weeks (nothing to do with fin efficacy, just experimenting).
The user experienced significant hair thickening after using topical minoxidil and oral finasteride for about 5 months and is considering switching from finasteride to RU58841. Other users encourage the original poster to continue the current treatment due to the positive results.
community I spoke to the Guy who did the Ru58841 (PSK-3841) research
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
community Every Single RU58841 Study Analysed - Youtube Video
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Related Research
6 / 88 results
research Experimental and Early Investigational Drugs for Androgenetic Alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Investigational Medications in the Treatment of Alopecia
New treatments for hair loss are being developed using molecular biology.
research Antiandrogens and Androgen Inhibitors in Dermatologic Treatments
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Alopecia: The Search for Novel Agents Continues
Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.
research Alopecia
The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.
research Drug Discovery for Alopecia: Gone Today, Hair Tomorrow
Topical drugs and near-infrared light therapy show potential for treating alopecia.